{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:40:34Z","timestamp":1787496034774,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,11,23]],"date-time":"2016-11-23T00:00:00Z","timestamp":1479859200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s00296-016-3612-2","type":"journal-article","created":{"date-parts":[[2016,11,23]],"date-time":"2016-11-23T00:55:01Z","timestamp":1479862501000},"page":"299-303","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Effects of febuxostat on insulin resistance and expression of high-sensitivity C-reactive protein in patients with primary gout"],"prefix":"10.1007","volume":"37","author":[{"given":"Juan","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuewu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,23]]},"reference":[{"key":"3612_CR1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.rdc.2014.01.001","volume":"40","author":"E Roddy","year":"2014","unstructured":"Roddy E, Choi HK (2014) Epidemiology of gout. Rheum Dis Clin North Am 40:155\u2013175","journal-title":"Rheum Dis Clin North Am"},{"key":"3612_CR2","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/BOR.0b013e32835d951e","volume":"25","author":"C Li","year":"2013","unstructured":"Li C, Hsieh MC, Chang SJ (2013) Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol 25:210\u2013216","journal-title":"Curr Opin Rheumatol"},{"key":"3612_CR3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11883-014-0419-z","volume":"16","author":"F Paneni","year":"2014","unstructured":"Paneni F, Costantino S, Cosentino F (2014) Insulin resistance, diabetes, and cardiovascular risk. Curr Atheroscler Rep 16:419","journal-title":"Curr Atheroscler Rep"},{"key":"3612_CR4","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1503\/cmaj.101430","volume":"183","author":"GM Reaven","year":"2011","unstructured":"Reaven GM (2011) Insulin resistance: from bit player to centre stage. CMAJ 183:536\u2013537","journal-title":"CMAJ"},{"key":"3612_CR5","first-page":"253","volume":"63","author":"F Viazzi","year":"2011","unstructured":"Viazzi F, Leoncini G, Pontremoli R (2011) Cardiovascular and renal effects of hyperuricemia and gout. Reumatismo 63:253\u2013262","journal-title":"Reumatismo"},{"key":"3612_CR6","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s11926-010-0084-3","volume":"12","author":"A Shah","year":"2010","unstructured":"Shah A, Keenan RT (2010) Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect? Curr Rheumatol Rep 12:118\u2013124","journal-title":"Curr Rheumatol Rep"},{"key":"3612_CR7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/BOR.0b013e3282f4b1ed","volume":"20","author":"JG Puig","year":"2008","unstructured":"Puig JG, Martinez MA (2008) Hyperuricemia, gout and the metabolic syndrome. Curr Opin Rheumatol 20:187\u2013191","journal-title":"Curr Opin Rheumatol"},{"key":"3612_CR8","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40265-015-0360-7","volume":"75","author":"JE Frampton","year":"2015","unstructured":"Frampton JE (2015) Febuxostat: a review of its use in the treatment of hyperuricemia in patients with gout. Drugs 75:427\u2013438","journal-title":"Drugs"},{"key":"3612_CR9","first-page":"11","volume":"435","author":"L Mayans","year":"2015","unstructured":"Mayans L (2015) Metabolic syndrome: insulin resistance and prediabetes. FP Essent 435:11\u201316","journal-title":"FP Essent"},{"key":"3612_CR10","first-page":"571","volume":"28","author":"P Chou","year":"2001","unstructured":"Chou P, Lin KC, Lin HY, Tsai ST (2001) Gender differences in the relationships of serum uric acid with fasting serum insulin and plasma glucose in patients without diabetes. J Rheumatol 28:571\u2013576","journal-title":"J Rheumatol"},{"key":"3612_CR11","first-page":"508409","volume":"2015","author":"L Chen","year":"2015","unstructured":"Chen L, Chen R, Wang H, Liang F (2015) Mechanisms linking inflammation to insulin resistance. Int J Endocrinol 2015:508409","journal-title":"Int J Endocrinol"},{"key":"3612_CR12","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1097\/MJT.0b013e3180a724b3","volume":"16","author":"V Chahwala","year":"2009","unstructured":"Chahwala V, Arora R (2009) Cardiovascular manifestations of insulin resistance. Am J Ther 16:e14\u2013e28","journal-title":"Am J Ther"},{"key":"3612_CR13","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ecl.2008.05.001","volume":"37","author":"B Razani","year":"2008","unstructured":"Razani B, Chakravarthy MV, Semenkovich CF (2008) Insulin resistance and atherosclerosis. Endocrinol Metab Clin North Am 37:603\u2013621","journal-title":"Endocrinol Metab Clin North Am"},{"key":"3612_CR14","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2337\/diacare.22.5.818","volume":"22","author":"M Emoto","year":"1999","unstructured":"Emoto M, Nishizawa Y, Maekawa K, Hiura Y, Kanda H, Kawagishi T, Shoji T, Okuno Y, Morii H (1999) Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care 22:818\u2013822","journal-title":"Diabetes Care"},{"key":"3612_CR15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1573399810666140214093600","volume":"10","author":"E Cersosimo","year":"2014","unstructured":"Cersosimo E, Solis-Herrera C, Trautmann ME, Malloy J, Triplitt CL (2014) Assessment of pancreatic beta-cell function: review of methods and clinical applications. Curr Diabetes Rev 10:2\u201342","journal-title":"Curr Diabetes Rev"},{"issue":"Suppl 2","key":"3612_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007995.2015.1087985","volume":"31","author":"C Borghi","year":"2015","unstructured":"Borghi C (2015) The role of uric acid in the development of cardiovascular disease. Curr Med Res Opin 31(Suppl 2):1\u20132","journal-title":"Curr Med Res Opin"},{"key":"3612_CR17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11926-015-0495-2","volume":"17","author":"AM Abeles","year":"2015","unstructured":"Abeles AM (2015) Hyperuricemia, gout, and cardiovascular disease: an update. Curr Rheumatol Rep 17:13","journal-title":"Curr Rheumatol Rep"},{"key":"3612_CR18","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1586\/14779072.2014.957675","volume":"12","author":"C Borghi","year":"2014","unstructured":"Borghi C, Verardi FM, Pareo I, Bentivenga C, Cicero AF (2014) Hyperuricemia and cardiovascular disease risk. Expert Rev Cardiovasc Ther 12:1219\u20131225","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"3612_CR19","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1559-4564.2006.05538.x","volume":"1","author":"CE Ndumele","year":"2006","unstructured":"Ndumele CE, Pradhan AD, Ridker PM (2006) Interrelationships between inflammation, C-reactive protein, and insulin resistance. J Cardiometab Syndr 1:190\u2013196","journal-title":"J Cardiometab Syndr"},{"key":"3612_CR20","first-page":"35","volume":"8","author":"I Saito","year":"2014","unstructured":"Saito I, Maruyama K, Eguchi E (2014) C-reactive protein and cardiovascular disease in East asians: a systematic review. Clin Med Insights Cardiol 8:35\u201342","journal-title":"Clin Med Insights Cardiol"},{"issue":"Suppl 2","key":"3612_CR21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1185\/03007995.2015.1087980","volume":"31","author":"F Perez-Ruiz","year":"2015","unstructured":"Perez-Ruiz F, Becker MA (2015) Inflammation: a possible mechanism for a causative role of hyperuricemia\/gout in cardiovascular disease. Curr Med Res Opin 31(Suppl 2):9\u201314","journal-title":"Curr Med Res Opin"},{"key":"3612_CR22","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/rheumatology\/keq037","volume":"49","author":"E Krishnan","year":"2010","unstructured":"Krishnan E (2010) Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout. Rheumatology (Oxford) 49:1229\u20131238","journal-title":"Rheumatology (Oxford)"},{"key":"3612_CR23","doi-asserted-by":"crossref","first-page":"12901","DOI":"10.1074\/jbc.M110.172460","volume":"286","author":"FC Meotti","year":"2011","unstructured":"Meotti FC, Jameson GN, Turner R, Harwood DT, Stockwell S, Rees MD, Thomas SR, Kettle AJ (2011) Urate as a physiological substrate for myeloperoxidase: implications for hyperuricemia and inflammation. J Biol Chem 286:12901\u201312911","journal-title":"J Biol Chem"},{"key":"3612_CR24","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3109\/10799893.2015.1006332","volume":"35","author":"S Yu","year":"2015","unstructured":"Yu S, Ren Q, Wu W (2015) Effects of losartan on expression of monocyte chemoattractant protein-1 (MCP-1) in hyperuricemic nephropathy rats. J Recept Signal Transduct Res 35:458\u2013461","journal-title":"J Recept Signal Transduct Res"},{"key":"3612_CR25","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/ndt\/gfg140","volume":"18","author":"T Umekawa","year":"2003","unstructured":"Umekawa T, Chegini N, Khan SR (2003) Increased expression of monocyte chemoattractant protein-1 (MCP-1) by renal epithelial cells in culture on exposure to calcium oxalate, phosphate and uric acid crystals. Nephrol Dial Transplant 18:664\u2013669","journal-title":"Nephrol Dial Transplant"},{"key":"3612_CR26","doi-asserted-by":"crossref","first-page":"e75527","DOI":"10.1371\/journal.pone.0075527","volume":"8","author":"J Nomura","year":"2013","unstructured":"Nomura J, Busso N, Ives A, Tsujimoto S, Tamura M, So A, Yamanaka Y (2013) Febuxostat, an inhibitor of xanthine oxidase, suppresses lipopolysaccharide-induced MCP-1 production via MAPK phosphatase-1-mediated inactivation of JNK. PLoS ONE 8:e75527","journal-title":"PLoS ONE"},{"key":"3612_CR27","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.clinthera.2015.03.026","volume":"37","author":"T Fukui","year":"2015","unstructured":"Fukui T, Maruyama M, Yamauchi K, Yoshitaka S, Yasuda T, Abe Y (2015) Effects of febuxostat on oxidative stress. Clin Ther 37:1396\u20131401","journal-title":"Clin Ther"},{"key":"3612_CR28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1517\/14656566.2015.985588","volume":"16","author":"MB Bridgeman","year":"2015","unstructured":"Bridgeman MB, Chavez B (2015) Febuxostat for the treatment of gout. Expert Opin Pharmacother 16:395\u2013398","journal-title":"Expert Opin Pharmacother"},{"key":"3612_CR29","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/RHU.0000000000000168","volume":"20","author":"G Saviola","year":"2014","unstructured":"Saviola G, Benucci M, Abdi-Ali L, Sacco S, Cera I, Rossini M (2014) Can febuxostat reduce triglyceride and cholesterol serum levels in gouty patients? J Clin Rheumatol 20:394\u2013395","journal-title":"J Clin Rheumatol"},{"key":"3612_CR30","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jjcc.2014.12.017","volume":"66","author":"A Sezai","year":"2015","unstructured":"Sezai A, Soma M, Nakata K, Osaka S, Ishii Y, Yaoita H, Hata H, Shiono M (2015) Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD). J Cardiol 66:298\u2013303","journal-title":"J Cardiol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-016-3612-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-016-3612-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-016-3612-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T08:56:14Z","timestamp":1601196974000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-016-3612-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,23]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["3612"],"URL":"https:\/\/doi.org\/10.1007\/s00296-016-3612-2","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,23]]}}}